Article
The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC.
Scientific reports - 5 May 2021
Tamiya Motohiro, Tamiya Akihiro, Okamoto Norio, Taniguchi Yoshihiko, Nishino Kazumi, Atagi Shinji, Hirashima Tomonori, Imamura Fumio, Kumagai Toru, Suzuki Hidekazu
Abstract excerpt
The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa group) may provide better outcomes for T790M-positive non-small cell lung cancer (NSCLC) than 1st-G EGFR-TKI followed by osimertinib (1st-G group). We studied 111 consecutive...
Topics
- Acrylamides
- Adult
- Aged
- Aged, 80 and over
- Aniline Compounds
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Epidermal Growth Factor
- Female
- Humans
- Lung Neoplasms
- Male
- Middle Aged